.After raising $170 million back in February, metabolic disease-focused BioAge Labs has submitted to debut on the general public market.The Eli Lilly-partnered biotech hopes to provide on the Nasdaq under the symbol "BIOA," according to records filed along with the Securities and Exchange Percentage. The business has not publicly discussed an anticipated monetary quantity for the offering.The clinical-stage business proclaims lead candidate azelaprag, a by mouth delivered little particle slated to enter stage 2 screening in combination along with semaglutide-- offered through Novo Nordisk under brand name Wegovy for weight-loss-- in the first one-half of next year. Semaglutide is additionally marketed as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is actually developed to mix properly with GLP-1 medicines, increasing weight management while maintaining muscle mass. The investigational medication was actually found to become well-tolerated amongst 265 people all over eight phase 1 trials, depending on to BioAge.Previously, BioAge gathered the help of Lilly to operate a test incorporating azelaprag with the Major Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and Zepbound for weight management. The companions are actually currently conducting a stage 2 test of azelaprag and also tirzepatide, with topline outcomes expected in the third fourth of 2025.The biotech is actually additionally preparing an insulin sensitiveness proof-of-concept trial determining azelaprag as a monotherapy in the first one-half of following year to assist possible indication growth. On top of that, the provider prepares to talk to the FDA for authorization in the 2nd half of 2025 to introduce individual testing for an NLRP3 inhibitor targeting metabolic conditions and neuroinflammation.BioAge's expected move to the general public market complies with a light uptick in planned biotech IPOs coming from Bicara Rehabs as well as Zenas Biopharma. Zooming out, the current IPO yard is a "combined photo," along with top quality companies still debuting on everyone markets, simply in minimized varieties, according to PitchBook.